University of Trieste

Enthera Pharmaceuticals Appoints Filippo Canducci as Chief Medical Officer

Retrieved on: 
Thursday, February 16, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, MBA, Roche, SDA Bocconi School of Management, Therapy, Inflammatory bowel disease, Medication, T1D, Mab, Drug development, University, IBD, Knowledge, Infection, University of Trieste, Doctor of Philosophy, MD, Pharmaceutical industry

Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer.

Key Points: 
  • Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer.
  • Dr. Canducci brings more than 20 years of experience in translational medicine, clinical research and drug development in inflammatory and autoimmune diseases.
  • Prior to joining Enthera, Dr. Canducci was a senior medical leader at Roche where he led global teams in the clinical development of immunology and infectious disease assets from clinical entry through transitioning to Phase 3.
  • Dr. Canducci has been published in more than 80 scientific papers in peer-reviewed high impact journals.

Fondazione Ernesto Illy and illycaffè Inaugurate the 12th Academic Year of the Ernesto Illy Master's Degree in Coffee Science and Economics

Retrieved on: 
Thursday, January 12, 2023
Economics, University of Udine, Illy, International Coffee Organization, Woman, Engineering, KEDGE Business School, International School for Advanced Studies, University of Copenhagen, Drexel University, University, Student, Culture, Environment, Master, Restaurant, Art, Beauty, International school, Centre de coopération internationale en recherche agronomique pour le développement, Science, Collection, University of Trieste, SISSA, B Corporation (certification), Ernesto Illy, Coffee, Management

TRIESTE, Italy, Jan. 12, 2023 /PRNewswire/ -- The 12th Academic Year of the Ernesto Illy First-level Inter-University Master's Degree in Coffee Science and Economics was inaugurated.

Key Points: 
  • TRIESTE, Italy, Jan. 12, 2023 /PRNewswire/ -- The 12th Academic Year of the Ernesto Illy First-level Inter-University Master's Degree in Coffee Science and Economics was inaugurated.
  • The Ernesto Illy Master's Degree in Coffee Science and Economics, the only one of its kind in the world, confirms Trieste's standing a global hub of coffee culture.
  • By the end of the programme, 249 people from 25 different countries will have earned a Master's Degree in Coffee Science and Economics.
  • Since 2016, with the "Ernesto Illy International Coffee Award", the company has celebrated coffee growers all over the world that, according to illy, have produced the best sustainable coffee.

SCOR supports actuarial science by presenting Actuarial Awards in five countries in 2022

Retrieved on: 
Friday, December 23, 2022
Transfer, University of Lausanne, Uncertainty, Sapienza University of Rome, Research, University of Ulm, Role, SCOR, Mortality, Risk, Thought, Music school, ENSAE, University of Trieste, Deep learning, Prix, Conservatoire national des arts et métiers, University, Machine learning, CNAM, Conference, Technical University of Kaiserslautern, Actuary, Fair, Risk management, Stockholm University, Pharmaceutical industry, Insurance, Life insurance, Science

The Actuarial Awards in France are supported by the SCOR Corporate Foundation for Science, chaired by André Lévy-Lang.

Key Points: 
  • The Actuarial Awards in France are supported by the SCOR Corporate Foundation for Science, chaired by André Lévy-Lang.
  • The SCOR Actuarial Awards juries are composed of internationally recognized researchers and insurance, reinsurance and finance professionals.
  • In 2022, SCOR presented Actuarial Awards in five countries: Germany, France, Italy, Sweden and Switzerland.
  • The award-winning papers can be accessed from the Actuarial Awards page on SCOR’s website:
    More SCOR Actuarial Awards will be presented again next year.

Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association

Retrieved on: 
Monday, November 7, 2022
American Heart Association, Protein, FTSE, Research, Science, Therapy, Heart, ICGEB, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Autophagy, International Centre, Genetic engineering, Industry, Apoptosis, BMP4, Mouse, Death, Scale of Protective Factors, Adult, Knowledge, AAV, British Heart Foundation, University of Trieste, Stroke, Health, University, Phenotype, Genetics, BHF, AMI, Risk, Myocardial infarction, Disease, AHA, Patient, Heart failure, Medical device, Vaccine, Pharmaceutical industry, Biology

London UK, 7 November 2022 Forcefield Therapeutics (Forcefield) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.

Key Points: 
  • London UK, 7 November 2022 Forcefield Therapeutics (Forcefield) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.
  • The paper presented preclinical data outlining the mechanisms of three proteins identified by FunSel, Forcefields protein search engine.
  • It has been further developed by Mauro Giacca, Professor of Cardiovascular Sciences at Kings College London and co-founder of Forcefield Therapeutics and supported by the British Heart Foundation.
  • Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes.

Researchers identify three proteins which have the potential to prevent heart failure after heart attack

Retrieved on: 
Wednesday, August 31, 2022
Center, British Heart Foundation, University, Public health, Research, Human, Heart failure, King Hamad University of Nursing and Associated Medical Sciences, Islamabad, Therapy, Time, Protein, Infarction, Death, MI, BHF, Mouse, QS World University Rankings, Heart, Kings, International Centre, Health, AMI, Disease management, Erosion (morphology), Force field, Prognosis, University of Trieste, Science, Cell, Student, Disability, FTSE, Stroke, Genetic engineering, Sri Jayadeva Institute of Cardiovascular Sciences and Research, ICGEB, Risk, Cell death, FAM3B, QS, REF, FAM3C, Cardiology, Drug development, Science Translational Medicine, Bias, Patient, King, Pharmaceutical industry, Medical device, Biology

Heart failure is the primary cause of death and disability globally, affecting approximately 64 million people worldwide according to the British Heart Foundation.

Key Points: 
  • Heart failure is the primary cause of death and disability globally, affecting approximately 64 million people worldwide according to the British Heart Foundation.
  • According to the British Heart Foundation, one person every five minutes is admitted to hospital with a heart attack in the UK.
  • Heart failure after a heart attack is caused by the irreversible loss of cardiac cells, hence the need to develop effective therapies to prevent the death of these cells.
  • Prof. Giacca added: Any of the three proteins we have identified can be administered immediately after a heart attack to minimise cardiac damage and thus prevent heart failure.